Molecular Partners (Switzerland) Today
| MOLN Stock | CHF 5.10 0.28 5.81% |
Performance2 of 100
| Odds Of DistressLess than 19
|
Molecular Partners is selling for under 5.10 as of the 4th of December 2024; that is 5.81 percent increase since the beginning of the trading day. The stock's lowest day price was 4.89. Molecular Partners has less than a 19 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Molecular Partners AG are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of November 2024 and ending today, the 4th of December 2024. Click here to learn more.
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland. MOLECULAR PARTNERS operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. The company has 36.04 M outstanding shares. More on Molecular Partners AG
Moving together with Molecular Stock
Moving against Molecular Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Molecular Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Molecular Partners' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Molecular Partners or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Molecular Partners AG (MOLN) is traded on SIX Swiss Exchange in Switzerland and employs 163 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 215.91 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Molecular Partners's market, we take the total number of its shares issued and multiply it by Molecular Partners's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Molecular Partners operates under Healthcare sector and is part of Biotechnology industry. The entity has 36.04 M outstanding shares.
Molecular Partners AG has accumulated about 267.13 M in cash with (90.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Molecular Partners Probability Of Bankruptcy
Ownership AllocationMolecular Partners maintains a total of 36.04 Million outstanding shares. 30% of Molecular Partners outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Molecular Ownership Details
Molecular Partners Risk Profiles
Although Molecular Partners' alpha and beta are two of the key measurements used to evaluate Molecular Partners' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.89 | |||
| Semi Deviation | 4.29 | |||
| Standard Deviation | 5.85 | |||
| Variance | 34.23 |
Molecular Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Molecular Partners without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Search Now
Equity SearchSearch for actively traded equities including funds and ETFs from over 30 global markets |
| All Next | Launch Module |
Molecular Partners Corporate Management
Elected by the shareholders, the Molecular Partners' board of directors comprises two types of representatives: Molecular Partners inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Molecular. The board's role is to monitor Molecular Partners' management team and ensure that shareholders' interests are well served. Molecular Partners' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Molecular Partners' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Steiner | VP Research | Profile | |
| Thomas Schwerzmann | VP HR | Profile | |
| Michael Stumpp | Ex CoFounder | Profile | |
| Andreas EMBA | Advisor | Profile | |
| Alexander Zurcher | COO Board | Profile | |
| Seth Lewis | Communications Relations | Profile |
Additional Tools for Molecular Stock Analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.